ArsenalBio Secures $325M with Regeneron, BMS Backing
ArsenalBio raises $325M to advance solid tumor CAR-T therapies. Focus on kidney, prostate cancer with innovative genomic technology.
- Latest
- Trending
ArsenalBio raises $325M to advance solid tumor CAR-T therapies. Focus on kidney, prostate cancer with innovative genomic technology.
Natera Inc. sees a 58% revenue surge in Q2 2024, driven by high test volumes and ASP growth, raising guidance ...
DaVita increases 2024 profit outlook due to high demand for kidney dialysis services, boosting shares by 3% in aftermarket trade.
Connecticut firefighters sue DuPont, 3M, and Honeywell over cancer-causing PFAS in gear. Learn about the health risks and lawsuit details.
Global medical technology company, Baxter International, has announced a quarterly cash dividend of $0.29 per share. This demonstrates their commitment ...
Stock futures dip as investors await inflation report release. ZoomInfo beats expectations, Arista Networks and Cadence Design Systems decline. S&P ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.